The result was announced during trading hours today, 3 February 2012.
Meanwhile, the BSE Sensex was up 149.57 points, or 0.86%, to 17,581.42
On BSE, 1.98 lakh shares were traded in the counter as against an average daily volume of 26,000 shares in the past two weeks.
The stock hit a high of Rs 1688.80 and a low of Rs 1636 so far during the day. The stock had hit a 52-week low of Rs 1387 on 22 August 2011. The stock had hit a record high of Rs 1716 on 2 May 2011.
The large-cap pharmaceutical company has an equity capital of Rs 84.76 crore. Face value per share is Rs 5.
In a press release, Dr Reddys Laboratories said it clocked highest net profit and sales figures in Q3 December 2012. Gross profit margin at 60% to revenues in Q3 December 2011 had improved largely due to favorable mix of high margin olanzapine revenues and benefit of rupee depreciation. The company had 33 new generic launches, 16 new generic filings and 7 DMF filings in Q3 December 2011.
Established in 1984, Dr. Reddys Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, differentiated formulations and News Chemical Entities (NCEs).
Powered by Capital Market - Live News
